RP
HUMA icon

Rowlandmiller & Partners’s Humacyte HUMA Stock Holding History

Rowlandmiller & Partners’s Portfolio HUMA Stock Details HUMA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-49,300
Closed -$103K – 190
2025
Q2 		$103K Buy
+49,300
New +$94.7K 0.02% 184
2025
Q1 		– Sell
-31,500
Closed -$159K – 188
2024
Q4 		$159K Buy
+31,500
New +$156K 0.03% 152

Other funds holding HUMA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Rowlandmiller & Partners's HUMA Position: Q3 2025 in Review

Rowlandmiller & Partners sold out of Humacyte (HUMA) in Q3 2025, closing a stake of 49,300 shares — an estimated $103K sold.

Rowlandmiller & Partners first reported a position in HUMA in Q4 2024 and held it in 2 quarters. The position peaked at $159K in Q4 2024. 141 funds tracked by Wall St. Rank hold HUMA as of Q3 2025.

  • Rowlandmiller & Partners reported no remaining Humacyte position as of Q3 2025 after selling out during the quarter.
  • Rowlandmiller & Partners sold 49,300 Humacyte shares in Q3 2025, an estimated $103K.
  • Rowlandmiller & Partners first reported a position in Humacyte in Q4 2024 and held it in 2 quarters.
  • Rowlandmiller & Partners's Humacyte position peaked at $159K in Q4 2024.
  • 141 funds tracked by Wall St. Rank held Humacyte as of Q3 2025.

Based on Rowlandmiller & Partners's 13F filing for Q3 2025, filed 1 Oct 2025.